Stock Groups

Novavax applies for COVID-19 vaccine approval in Switzerland -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: This illustration, taken October 30, 2020 shows a woman holding a small plastic bottle with the Novavax logo on it. REUTERS/Dado Ruvic

(Reuters) – Novavax (NASDAQ:) Inc submitted a request to Switzerland’s drug regulator for authorization of COVID-19 in adults. The U.S. vaccine manufacturer said Monday.

This submission was based upon data from key clinical trials that were conducted in Mexico and the United States, as well as the UK. These studies showed that the vaccine is 90% effective against COVID-19.

Novavax’s vaccine based on protein is under review by U.S. Food and Drug Administration. It has also received approvals from both the European Union and World Health Organization.

The vaccine has been approved for adult use in Australia, New Zealand, and the UK. Last week, the company announced that its vaccine had been approved for use in adults in countries such as Australia and New Zealand.

 

 

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]